C-LEPPAmprion
seed amplification assay, alpha-synuclein, CSF diagnostics
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-LEPP
C-LEPPC-LEPPseed amplification assay, alpha-synuclein, CSF diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Amprion presents itself as a pioneer in Prion Detection Science and states that biomarker testing can accurately detect misfolded proteins associated with brain diseases, thereby improving diagnosis of synucleinopathies including Parkinson's disease, Lewy body dementia, Alzheimer's disease with Lewy bodies, multiple system atrophy, and mild cognitive impairment with Lewy bodies. The company frames its work as translating decades of research into clinically useful diagnostics that improve diagnostic accuracy for brain disorders.
SourceAmprion states that it is a pioneer in prion detection science and believes biomarker testing can accurately detect misfolded proteins associated with brain diseases, improving physicians’ ability to diagnose synucleinopathies such as Parkinson’s disease and Lewy body dementia. It presents SYNTap as a way to improve diagnostic accuracy and says it plans to expand with additional biomarker tests in the future.
SourceAmprion presents itself as focused on ultra-sensitive diagnosis of neurodegenerative diseases and implies that these diseases can be understood and detected through protein-misfolding biology, particularly via its PMCA technology built around abnormal protein behavior associated with brain disease.
Source